Centessa Pharmaceuticals PLC (LTS:0ACX)

$ 17.47 -1 (-5.41%) Market Cap: 2.38 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 4.56 GF Score: 19/100

Centessa Pharmaceuticals PLC at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Mar 31, 2022
Centessa Pharmaceuticals PLC -To Discuss ZF874 Phase 1 Part B results in Alpha-1 Antitrypsin Deficiency Transcript
Nov 01, 2021
Centessa Pharmaceuticals PLC Discuss Topline Data from Proof-of-Concept Study of SerpinPC Trial Call Transcript
Sep 09, 2021

Centessa Pharmaceuticals PLC -To Discuss ZF874 Phase 1 Part B results in Alpha-1 Antitrypsin Deficiency Transcript

Nov 01, 2021 / 12:30PM GMT

Transcript 10-Q8-K

Operator

Good morning everyone. Welcome to Centessa Pharmaceuticals ZF874 Phase 1 Part B Update conference call. At this time, all participants are in a listen-only mode. Please note that this call may be recorded.

I will now hand the call over to Jennifer Porcelli, Centessa's head of Investor Relations. Please go ahead, ma'am.

Jennifer Porcelli

Centessa Pharmaceuticals - Head of Investor Relations

Thank you and good morning, everyone. We are pleased you can join us today for this interim update on our Phase 1 Part B multiple dose study of ZF874 in subjects with at least one Z alpha-1-antitrypsin allele. Please refer to our press release from this morning as well as the corresponding data presentation, both of which are available on our website.

During this call, we will be making forward-looking statements. These statements include, without limitation, discussions of the Phase 1 study of ZF874, and its design and conduct, plans for continued development of ZF874, including our planned Phase 2 study and modifications to the ongoing Phase 1.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.